Loading…
Based on limited metadata, RxAff received an FDA Warning Letter on October 9, 2018, regarding drug products under the agency's regulatory authority. Without access to the full letter text or detailed subject information, the specific nature of the violations cannot be definitively characterized from the available metadata alone. The warning relates to drug manufacturing, marketing, or compliance practices subject to FDA oversight. Additional documentation would be needed to identify the precise regulatory violations and corrective actions required.